Author(s) : J-Y Blay, F Eisinger, O Rixe, A Calazel-Benque, J-F Morère, L Cals, Y Coscas, S Dolbeault, M Namer, D Serin, C Roussel, X Pivot , Inserm U590, centre Léon-Bérard, UJOMM HEH & Conticanet FP6-018806, 69373 Lyon, France, Department of Oncogenetics Screening and Prevention, Paoli-Calmettes Institute, 13009 Marseille, France, Inserm U599, 13009 Marseille, France, Hôpital de La Pitié-Salpêtrière, 75013 Paris, France, Capio clinique du Parc, 31400 Toulouse, France, Hôpital Avicenne, 93000 Bobigny, France, Hôpital Font-Pré, 83100 Toulon, France, Clinique de la Porte-de-Saint-Cloud, 92100 Boulogne-Billancourt, France, Psycho-Oncology Unit, Curie Institute, 75020 Paris, France, Centre azuréen de cancérologie, 06250 Mougins, France, Institut Sainte-Catherine, 84000 Avignon, France, Laboratoire Roche, boulevard du Parc, 92000 Neuilly, France, CHU de Besançon, 25030 Besançon, France.
Summary : IntroductionThe practices of screening and the parameters influencing these practices are not well known in France. The objectives of the Edifice study were to analyze a large cohort of patients and doctors in order to further characterize these parameters.Patients and methodsThe study was performed by the Institute TNS Healthcare-SOFRES, and included 2 parallel studies: 1) on 1 609 healthy persons representative of the global French population and aged 40 to 75 years (N \= 1 509), with an over representation of patients aged 50 to 74 years living in the 22 pilot French departments pilots\; 2) on 600 generalist practitioners. Data were collected and analyzed by the expert panel…ResultsNinety-three, 25, 36 and 6% of the patients in the general population declared to have performed at least one a screening exam for breast, colon, prostate, and lung carcinoma respectively. Seventy, 20, 60 and 4% of GP declare to propose systematically to a 40-75-year-old patient a screening test for breast, colon, prostate, or lung cancer. For breast cancer screening the adhesion of the GP is independent of the date of implementation of a general screening in their own regions, while for colorectal screening, 34 and 20% of the patients living in the pilot versus other departments were screened. Overall, prostate cancer screening is recommended by the GP panel for 77.1% of patients aged 50 to 75 years.ConclusionsThis study shows a good adhesion of screening procedures for GP and patients, shows that screening is improved by general screening policy in colorectal cancer, but that prostate cancer screening practices exceed what is recommended according to evidence based medicine.
Figure 1 Bases : 507 femmes de 50-74 ans pour
le sein ; 970 individus de 50-74 ans pour le côlon ; 475
hommes de 50-75 ans pour la prostate ; 1 504 individus de
40-75 ans pour le poumon.
Figure 2 Base : 600 médecins généralistes (MG).*
Pour les patients sans antécédents particuliers, âgés de 50 à
74 ans pour les cancers du sein et du côlon, de 40 à
75 ans pour le cancer du poumon, de 50 à 75 ans pour le
cancer de la prostate.
Printable version
Version PDF
